Bladder preservation by neoadjuvant chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer: Experience at sindh institute of urology & transplantation (SIUT)

Journal of the Pakistan Medical Association

Volumn 61, Issue 1, 2011, Pages 6-10

  Tunio, Mutahir Ali ^a   Hashmi, Altaf ^a   Rafi, Mansoor ^a   Qayyum, Abdul ^a   Masood, Rehan ^a  

^a SINDH INSTITUTE OF UROLOGY AND TRANSPLANTATION   (Pakistan)

Author keywords

Cisplatinum; Concorrent chemoradiation; Gemcitabine; Muscle invasive bladder; Neoadjuvant chemotherapy

Indexed keywords

CISPLATIN; GEMCITABINE;

ADULT; AGED; ANOREXIA; ARTICLE; BLADDER BIOPSY; BLADDER CANCER; BLADDER IRRITATION; BONE METASTASIS; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CYSTECTOMY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HYDRONEPHROSIS; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHROTOXICITY; OVERALL SURVIVAL; PROGNOSIS; THROMBOCYTOPENIA; TRANSURETHRAL RESECTION; TRANSURETHRAL RESECTION OF BLADDER TUMOR; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMORADIOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; CYSTOSCOPY; DEOXYCYTIDINE; FEMALE; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 78651235560     PISSN: 00309982     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Joung JY, Han KS, Kim TS, Seo HK, Chung J, Lee KH. Single institutional experience of bladder-preserving trimodality treatment for muscle-invasive bladder cancer. J Korean Med Sci 2008; 23: 598-603.
2. Rodel C, Grabenbauer GC, Kuhn R, Papadopoulos T, Dunst J, Meyer M, et al. Combined modality treatment and selective organ preservation in invasive bladder cancer: long term results. J Clin Oncol 2002; 20: 3061-71.
3. Solsona E, Climent MA, Iborra I, Collado A, Rubio J, Ricos JV, et al.Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy. Eur Urol 2009; 55: 911-9.
4. Shipley WU, Kaufman DS, Zehr E, Heney NM, Lane SC, Thakral HK, et al. Selective bladder preservation by combined modality protocol treatment: long term outcomes of 190 patients with invasive bladder cancer. Urology 2002; 60: 62-8.
5. Clark PE. Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2009; 9: 821-30.
6. Kaufman DS, Winter KA, Shipley WU, Heney NM, Wallace HJ III, Toonkel LM, et al. Phase I-II RTOG study (99-06) of patients with muscle-invasive bladder cancer undergoing transurethral surgery, paclitaxel, cisplatin, and twicedaily radiotherapy followed by selective bladder preservation or radical cystectomy and adjuvant chemotherapy. Urology 2009; 73: 833-7.
7. Michaelson MD, Shipley WU, Heney NM, Zietman AL, Kaufman DS. Selective bladder preservation for muscle invasive transitional cell carcinoma of the urinary bladder. Br J cancer 2004; 90: 578-81.
8. Wallace DM, Raghavan D, Kelley K, Sandeman TF, Conn IG, Teriana N, et al. Neoadjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991; 67: 608-15.
9. Martinez-Pineiro JA, Gonzalez Martin M, Arocena F, Flores N, Roncero CR, Portillo JA, et al. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: a prospective randomized phase III study. J Urol 1995; 153: 964-73.
10. Hall RR. Neoadjuvant CMV chemotherapy and cystectomy or radiotherapy in muscle invasive bladder cancer: First analysis of MRC/EORTC intercontinental trial. Proc Am Soc Clin Oncol 1996; 15: 244.
11. Shipley WU, Winter KA, Kaufman DS, Lee WR, Heney NM, Tester WR, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998; 16: 3576-83.
12. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and metaanalysis. Lancet 2003; 361: 1927-34.
13. Winquist E, Kirchner TS, Segal R, Chin J, Lukka H; Genitourinary Cancer Disease Site Group, Cancer Care Ontario Program in Evidence-based Care Practice Guidelines Initiative. Neo-adjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. J Urol 2004; 171: 561-9.
14. Neo-adjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48: 202-5.
15. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter phase III study. J Clin Oncol 2000; 18: 3068-77.
16. Kaba H, Fukuda H, Yamamoto S, Ohashi Y. Reliability at the National Cancer Institute-Common Toxicity Criteria version 2.0. Gan To Kagaku Ryoho 2004; 31: 1187-92.
17. Yildirim G, Ozsaran Z, Yalman D, Kamer S, Aras A. Evaluation of acute and late radiation morbidity in patients with gynaecologic malignancy using the RTOG criteria and Franco-Italian glossary. Eur J Gynaecol Oncol 2008; 29: 154-7.
18. Tester W, Porter A, Asbell S, Coughlin C, Heaney J, Krall J, et al. Combined modality program with possible organ preservation for invasive bladder carcinoma: results of RTOG protocol 85-12. Int J Radiat Oncol Biol Phys 1993; 25: 783-90.
19. Lin CC, Hsu CH, Cheng JC, Huang CY, Tsai YC, Hsu FM, et al. Induction cisplatin and fluorouracil-based chemotherapy followed by concurrent chemoradiation for muscle-invasive bladder cancer. Int J Radiat Oncol Biol Phys 2009; 75: 442-8.
20. Cervek J, Cufer T, Kragelj B, Zakotnik B, Stanonik M. Sequential transurethral surgery, multiple drug chemotherapy and radiation therapy for invasive bladder carcinoma: initial report. Int J Radiat Oncol Biol Phys 1993; 25: 777-82.
21. Kaufman DS, Shipley WU, Griffin PP, Heney NM, Althausen AF, Efird JT. Selective bladder preservation by combination treatment of invasive bladder cancer. N Eng J Med 1993; 329: 1377-82.
22. Scrimger RA, Murtha AD, Parliament MB, Venner PM, Hanson J, Houle G, et al. Muscle-invasive transitional cell carcinoma of the urinary bladder: a population-based study of patterns of care and prognostic factors. Int J Radiat Oncol Biol Phys 2001; 51: 23-30.
23. Rodel C, Weiss C, Sauer R. Organ preservation by combined modality treatment in bladder cancer: the European perspective. Semin Radiat Oncol 2005; 15: 28-35.
24. Tunio M, Rafi M, Maqbool A, Haque A. Virtual simulation and treatment verification-merits and demerits: experience at Sindh Institute of Urology and Transplantation (SIUT), Pakistan. J Radiotherapy Practice 2009; 8: 131-6.
25. Deliveliotis C, Georgoulakis J, Skolarikos A, Trakas N, Varkarakis J, Albanis S, et al. DNA ploidy as a prognostic factor in muscle invasive transitional cell carcinoma of the bladder. Urol Res 2005; 33: 39-43.
26. Niu HT, Xu T, Zhang YB, Pang DQ, Zhang ZL, Wu S, et al. Outcomes for a large series of radical cystectomies for bladder cancer. Eur J Surg Oncol 2008; 34: 911-5.
27. Wulfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the secondline treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer 2009; 115: 2881-90.